Article
Oligodeoxynucleotide CpG 7909 delivered as intravenous infusion demonstrates immunologic modulation in patients with previously treated non-Hodgkin lymphoma.
Journal of immunotherapy (Hagerstown, Md. : 1997) - 1 Jan 2000
Link Brian K, Ballas Zuhair K, Weisdorf Daniel, Wooldridge James E, Bossler Aaron D, Shannon Mary, Rasmussen Wendy L, Krieg Arthur M, Weiner George J
Abstract excerpt
Oligodeoxynucleotides containing CpG motifs (CpG ODN) can alter various immune cell subsets important in antibody therapy of malignancy. We undertook a phase I trial of CPG 7909 (also known as PF-3512676) in patients with previously treated lymphoma with the primary objective of evaluating safety across a range of doses, and secondary objectives of evaluating immunomodulatory effects and clinical effects....
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.